|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300076621 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-13 09:32:27 |
|
注册时间: Date of Registration: |
2023-10-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新冠疫情不同时期 MHD 患者社会支持、焦虑-抑郁-压力、情绪调节与生活质量间的关系-网络分析 |
|
Public title: |
Relationship between social support, anxiety-depression-stress, emotion regulation and quality of life in patients with MHD in different periods of COVID-19 epidemic-network analysis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新冠疫情不同时期 MHD 患者社会支持、焦虑-抑郁-压力、情绪调节与生活质量间的关系-网络分析 |
|
Scientific title: |
Relationship between social support, anxiety-depression-stress, emotion regulation and quality of life in patients with MHD in different periods of COVID-19 epidemic-network analysis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吕红红 |
研究负责人: |
吕红红 |
|
Applicant: |
Lv Honghong |
Study leader: |
Lv Honghong |
|
申请注册联系人电话: Applicant telephone: |
+86 159 9179 2275 |
研究负责人电话: Study leader's telephone: |
+86 159 9179 2275 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
283360153@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
283360153@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市灞桥区新寺路569号 |
研究负责人通讯地址: |
陕西省西安市灞桥区新寺路569号 |
|
Applicant address: |
No. 569 Xinsi road, Baqiao district, Xi'an, Shaanxi province |
Study leader's address: |
No. 569 Xinsi road, Baqiao district, Xi'an, Shaanxi province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
第四军医大学唐都医院 |
||
|
Applicant's institution: |
Tangdu Hospital of the fourth military Medical University |
||
|
研究负责人所在单位: |
第四军医大学唐都医院 |
||
|
Affiliation of the Leader: |
Tangdu Hospital of the fourth military Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
第K202309-24号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
第四军医大学唐都医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Tangdu Hospital of the fourth military Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-09-13 00:00:00 |
||
|
伦理委员会联系人: |
李诗草 |
||
|
Contact Name of the ethic committee: |
Li Shicao |
||
|
伦理委员会联系地址: |
陕西省西安市灞桥区新寺路569号 |
||
|
Contact Address of the ethic committee: |
No. 569 Xinsi road, Baqiao district, Xi'an, Shaanxi province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 29 8477 7631 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
第四军医大学唐都医院肾脏内科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Nephrology, Tangdu Hospital, fourth military Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市灞桥区新寺路569号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 569 Xinsi road, Baqiao district, Xi'an, Shaanxi province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
唐都医院院课题项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The project of Tangdu Hospital |
||||||||||||||||||||||
|
Target disease: |
End-stage kidney disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
使用网络模型分析方法探讨新冠疫情不同时期(疫情爆发初期与后疫情时期)维持性血液透(Maintenance hemodialysis,MHD)患者 MSPSS 的家庭、朋友和重要他人三个维度与 KDQOL-TM36 各个维度的潜在关联路径及重要性,DERS 与 DASS-21 各维度潜在关联路径及重要性;MSPSS 在DERS 与KDQOLTM36 间的中介作用;使用R 软件对网络中各维度的强度和桥-强度中心性进行分析和可视化。 |
||||||||||||||||||||||
|
Objectives of Study: |
The network model analysis method was used to explore the potential correlation path and importance between the family, friends and important others of maintenance hemodialysis (Maintenance hemodialysis,MHD) patients' MSPSS in different periods of COVID-19 epidemic (early and post-epidemic period) and each dimension of KDQOL-TM36, and the potential correlation path and importance of each dimension of DERS and DASS-21. MSPSS in DERS and KDQOL. The intermediary role between TM36; use R software to analyze and visualize the strength and bridge-strength centrality of each dimension in the network. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)透析时间≥3 年; 2)年龄≥18 岁,无精神或神经系统疾病史; 3)自愿参与研究; 4)能够独立完成问卷或在研究者的帮助下完成问卷者 |
||||||||||||||||||||||
|
Inclusion criteria |
1) dialysis time ≥ 3 years. 2) Age ≥ 18 years old, no history of mental or nervous system disease. 3) volunteer to participate in the research. 4) those who can complete the questionnaire independently or with the help of researchers |
||||||||||||||||||||||
|
排除标准: |
1)沟通障碍患者; 2)长期或近期使用精神药物; 3)因其他原因拒绝或无法配合调查者; 4)严重器质性心脑血管疾病及认知障碍患者; 5)近 3 个月有重大病情变化者; 6)患有痴呆/精神错乱在过去一个月内紧急住院超过 7 天者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) patients with communication disorders. 2) long-term or short-term use of psychotropic substances. 3) those who refuse or are unable to cooperate with the investigation for other reasons. 4) patients with severe organic cardio-cerebrovascular diseases and cognitive impairment. 5) those who have significant changes in their illness in the past 3 months. 6) those with dementia / insanity who have been hospitalized urgently for more than 7 days in the past month. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-15 00:00:00至 To 2023-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-10-15 00:00:00 至 To 2023-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台ResMan,http://www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Clinical Trial Management Public Platform http://www.medresman.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record table |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |